Caesar, Rivise, Bernstein, Cohen and Pokotilow have announced that firm partner Robert Stevenson, a Mt. Laurel resident, was a featured speaker at the Sixth International Pharmaceutical R&D Summit in Shanghai, China. The summit was attended by several hundred members of the Chinese pharmaceutical and biotech industries and members of the academic community.
In one of his recent talks in China, Stevenson spoke on the importance and patent litigation aspects of the U.S. Abbreviated New Drug Application and New Biosimilars legislation to Chinese pharma and biotech companies exporting to the U.S. The Chinese government, according to government policies cited by Stevenson, is very interested in having its generic pharma industry become a major exporter to the US and the EU.
Stevenson has been counsel of record in over 25 federal patent litigation matters, has been a consultant on many others, and has supervised international litigation in China, Japan, Germany and the U.K. He also has over 29 years experience prosecuting world-wide patents and handling U.S. and international patent litigation involving the pharmaceutical, biotechnological, chemical, diagnostic, polymer, cosmetics, clinical trial and medical device arts. Prior to joining the firm, Stevenson was vice president of Cell Pathways, a publicly traded pharmaceutical company, and senior counsel to Abbott Labs. He is a former partner and chair of the pharma/biotech group at Brinks Hofer in Chicago and senior patent pounsel for Rohm and Haas.
A past adjunct professor of patent law at DePaul University School of Law, Stevenson is a member of the Pennsylvania and Illinois state bars and is registered to practice before the U.S. Patent and Trademark Office. A graduate of Penn State, he received his Masters Degree in Engineering from the University of Michigan and his law degree from Wayne State University.
